---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000121"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:47:37.253279+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025

## Summary
- Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.
- Phase 1b randomized comparison: 600mg RP2D showed 83.3% ORR vs 73.7% for 200mg; PFS trend favoring 600mg.
- WM (n=28 evaluable) ORR 75.0% including 10.7% VGPR; median follow-up 8.1 months, median DOR and PFS not reached.
- Safety: well tolerated across doses; no dose-limiting toxicities, systemic fungal infections, or Grade 4 infections.
- Pivotal Phase 2 DAYBreak-CLL-201 enrolling globally; 600mg RP2D selected for further development.

## SEC filing metadata
- accession: 0001549595-25-000121
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000121/0001549595-25-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000121/nrix-20251206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000121
- JSON: https://secwatch.observer/filing/0001549595-25-000121.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.